You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • SAT0329 Lesinurad, A Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout: the Crystal Phase III Clinical Trial

Article info

Article menu
Download PDFPDF
Poster Presentations
Bone diseases other than osteoporosis, metabolic diseases and crystal diseases
SAT0329 Lesinurad, A Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout: the Crystal Phase III Clinical Trial

Authors

Citation

Dalbeth N, Jones G, Terkeltaub R, et al
SAT0329 Lesinurad, A Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout: the Crystal Phase III Clinical Trial
Annals of the Rheumatic Diseases 2015;74:778.

Publication history

  • First published June 9, 2015.
Online issue publication 
February 26, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions